Aidoc’s CARE AI Recognized in TIME’s Best Inventions of 2026
Israeli medical technology firm Aidoc has achieved a significant milestone with its artificial intelligence model, CARE, being honored as one of the Best Inventions of 2026 in the Medicine and Health category by TIME magazine. This recognition underscores the transformative potential of AI in healthcare.
Innovative AI Model for Early Detection
The CARE model analyzes medical imaging and clinical documentation, facilitating earlier identification of serious medical conditions. According to TIME’s selection committee, the technology’s capacity to detect a diverse array of critical medical findings played a pivotal role in its nomination.
Prioritizing Critical Findings
When the CARE system identifies a potentially urgent medical issue, it flags the corresponding examination for immediate attention from medical teams. This functionality allows healthcare professionals to prioritize urgent cases more effectively. Furthermore, the model enhances Aidoc’s ability to identify various conditions without the need to create separate AI models for each one.
A Recognition of Impact and Innovation
TIME’s annual roundup of breakthroughs in innovation assesses inventions based on key criteria such as originality, effectiveness, ambition, and overall impact. The current list also features notable technologies, including Anthropic’s Claude Code and Lovable, placing Aidoc’s achievement among esteemed company.
Perspective from Aidoc’s Leadership
Aidoc’s CEO and co-founder, Elad Walach, expressed optimism regarding the advancements in medical AI. He stated, “Medical foundation models that can detect hundreds of diseases and significantly improve diagnostic safety are among the developments that will affect us all.” Walach highlighted the growing trend of AI acting as an additional safety measure in routine medical diagnostics.
“We are rapidly approaching a reality in which AI will serve as an additional pair of eyes in almost every medical diagnosis,” he added. This trend is exemplified by CARE’s growing significance as a component of Aidoc’s operations.
Deployment and Impact
The CARE model has received clearance from the U.S. Food and Drug Administration (FDA) and is actively used in over 150 healthcare systems across the United States, as well as in more than 1,600 hospitals around the globe, including the majority of hospitals in Israel.
Company Background and Funding
Founded in 2016 by Elad Walach, Michael Braginsky, and Guy Reiner, Aidoc specializes in AI-driven platforms that scrutinize medical imaging and clinical data to alert healthcare providers regarding life-threatening conditions, thus enabling timely intervention.
The company has successfully raised over $500 million in funding, drawing interest from prominent venture capital entities, including General Catalyst, TLV Partners, and SoftBank’s Vision Fund 2, among others. The latest funding round concluded in April 2026, securing $150 million under the leadership of Goldman Sachs’ growth investment division.
Future Directions
As Aidoc continues to refine the capabilities of its CARE model, the company aims to broaden the spectrum of medical conditions detectable by its technology while simultaneously enhancing the precision of its algorithms. This commitment positions Aidoc at the forefront of medical innovation, signifying a promising future for AI in enhancing healthcare delivery.
